Shares of Kadmon Holdings Inc (NASDAQ:KDMN) have received a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $9.85.
Several analysts have recently weighed in on KDMN shares. Zacks Investment Research lowered Kadmon Holdings from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Kadmon Holdings in a report on Monday, June 26th. Piper Jaffray Companies reissued a “buy” rating and set a $7.00 price objective on shares of Kadmon Holdings in a report on Friday, July 14th. Finally, ValuEngine lowered Kadmon Holdings from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.
In related news, major shareholder Goldentree Asset Management Lp sold 515,643 shares of the business’s stock in a transaction on Monday, June 26th. The stock was sold at an average price of $3.51, for a total value of $1,809,906.93. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders purchased 14,707 shares of company stock worth $34,294 and sold 1,840,331 shares worth $6,193,607.
Hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in shares of Kadmon Holdings during the second quarter valued at approximately $114,000. Vanguard Group Inc. increased its position in shares of Kadmon Holdings by 166.0% in the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after buying an additional 941,549 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Kadmon Holdings by 17.0% in the second quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock valued at $234,000 after buying an additional 8,742 shares during the last quarter. Sawtooth Solutions LLC increased its position in shares of Kadmon Holdings by 396.9% in the second quarter. Sawtooth Solutions LLC now owns 99,649 shares of the company’s stock valued at $388,000 after buying an additional 79,593 shares during the last quarter. Finally, Perceptive Advisors LLC increased its position in shares of Kadmon Holdings by 134.7% in the first quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock valued at $18,772,000 after buying an additional 2,976,190 shares during the last quarter.
Shares of Kadmon Holdings (KDMN) traded down 2.35% on Friday, reaching $2.08. 119,509 shares of the company traded hands. The firm has a 50-day moving average of $2.97 and a 200-day moving average of $3.11. Kadmon Holdings has a 52-week low of $2.05 and a 52-week high of $10.48. The company’s market capitalization is $107.84 million.
Kadmon Holdings (NASDAQ:KDMN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $3 million for the quarter, compared to analyst estimates of $3.46 million. During the same period in the previous year, the business posted ($4.40) EPS. Kadmon Holdings’s revenue for the quarter was down 53.1% compared to the same quarter last year. On average, equities research analysts forecast that Kadmon Holdings will post ($1.58) earnings per share for the current fiscal year.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
